ClinicalTrials.gg
Sign In

Drug

HRS-6209 clinical trials

Also written HRS-6209.

studies test it
4
open now
2
in phase 3
0
first study started
2022

Keep track of what changes. Save the HRS-6209 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

HRS-6209
3

Studies by the year they started

4 studies that test it; most in 2022 (1)

Studies that test HRS-6209, by start year
YearStudies
20221
20231
20251
20261

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
2

What it is tested for

Each study’s main condition, where its own words name it.

Breast Neoplasms
2
Triple Negative Breast Neoplasms
1

Who runs them

Industry 3 · Other 1

Jiangsu HengRui Medicine Co., Ltd. (2) · Fudan University (1) · Shandong Suncadia Medicine Co., Ltd. (1)

Often tested with

Tested in the same studies.

Dalpiciclib (1) · Pyrotinib (1) · Trastuzumab rezetecan (1) · Adebrelimab (1) · Camrelizumab (1) · Tizetatug rezetecan (1) · Pertuzumab (1) · Trastuzumab (1)

Studies

Open first, then newest update. How each study uses HRS-6209 is read from its arms, and is right about nine times in ten.

Testing it · 4

Given in every arm · 2 — HRS-6209 is usual care beside what is tested